Aim: The effects of giving corticosteroids to pregnant women and their unborn children in the late preterm phase. Material and methods: Pregnant women who are at risk of having a premature baby are divided into two groups: those who receive prenatal corticosteroids after 34 weeks of pregnancy and those who do not, in line with the current standard of treatment. The former entails giving the patient two 12-milligram shots of betamethasone intramuscularly, 24 hours apart. Singleton pregnancies between 340/7 and 366/7 weeks were eligible, as were parturient who were close to delivering; fetal death, significant congenital malformations, and chromosomal abnormalities were not. There were 100 test subjects who were exposed and 100 who were not. Results: ACS usage was greatest in the 340/7 to 346/7 week group (58% vs. 5%, p <0.001) and lowest in the 360/7 to 366/7 week category (13% vs. 70%, p <0.001). As a consequence, the study group's mean birth weight was lower (2801.74g vs. 2698.58g; p<0.043). In this research, the incidence of ACS administration as a function of gestational age was higher in patients at 34 weeks than in those at 36 weeks (58% vs. 13%, p <0.001). Preterm labour was the most common reason for delivery (45%), followed by premature preterm rupture of membranes (24%), hypertensive disorders of pregnancy (14%), antepartum haemorrhage (4%), fetal compromise (10%), and elective (1%). Except for higher rates of suspected sepsis (11% vs. 4%, p< 0.02; odds ratio (OR) 3.58, 95% confidence interval (CI) 1.37-7.85) and hypoglycemia (20% vs. 11%, p<0.04; OR 2.18, CI 1.22-4.61) in infants born to mothers exposed to ACS, there was no statistically significant difference in the rate of the primary outcome variable as well as the individual variables studied between the exposed. Conclusion: According to the results of this investigation, prenatal corticosteroids did not help prevent newborn morbidity. In fact, there was an increase in the number of neonates diagnosed with hypoglycemia and probable sepsis whose mothers were exposed to steroids. However, if the lack of benefit is verified by further research along with a trend towards increased problems, this treatment should typically be kept to experimental investigations. Antenatal Late Preterm Steroids (ALPS) is a big randomised controlled experiment that is currently recruiting participants and has the potential to settle this debate and standardise care for pregnant women who are at high risk of having their babies prematurely during the LPP.